San Diego-based mostly Viking Therapeutics marked alone as a significant competitor during the weight loss drug market in February after revealing promising facts from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in March the compa